COVID-19 patients who receive oxygen therapy or experience fever show reduced gray matter volume in the frontal-temporal network of the brain, according to a new study. The study's findings demonstrate changes to the frontal-temporal network could be used as a biomarker to determine the likely prognosis of COVID-19 or evaluate treatment options for the disease.